General characteristics of the included guidelines
| Serial number | Guidelines | Publish date | Number of pages | Number of authors | Number of references | Subject | Region | Organisation |
|---|---|---|---|---|---|---|---|---|
| 1 | Diuretics for hypertension: Chinese experts’ consensus22 | 2011 | 9 | 46 | 65 | Drug intervention | Chinese mainland | The Subspecialty Group of Hypertension, Society of Cardiology, Chinese Medical Association |
| 2 | 2010 Chinese guidelines for the management of hypertension23 | 2011 | 38 | 43 | 218 | Comprehensive management | Chinese mainland | Writing Group of 2010 Chinese Guidelines for the Management of Hypertension |
| 3 | Expert consensus on the clinical application of levamlodipine besylate24 | 2010 | 3 | 4 | 19 | Drug intervention | Chinese mainland | Cardiovascular Medicine Branch of China Medical Doctor Association; Cardio-cerebrovascular Disease Branch of Chinese Geriatrics Society |
| 4 | Expert consensus on diagnostic and treatment of Chinese emergency hypertension25 | 2010 | 12 | U | 35 | Emergency hypertension | Chinese mainland | Emergency Physicians Branch of Chinese Medical Doctor Association |
| 5 | Hong Kong reference framework for hypertension care for adults in primary care settings26 | 2010 | 40 | 82 | 0 | Comprehensive management | Hong Kong, China | Task Force on Conceptual Model and Preventive Protocols Working Group on Primary Care; Food and Health Bureau |
| 6 | 2010 Guidelines of the Taiwan Society of Cardiology for the management of hypertension27 | 2010 | 34 | 12 | 208 | Comprehensive management | Taiwan, China | Hypertension Committee of the Taiwan Society of Cardiology |
| 7 | Guidelines for the management of hypertension. Taiwan stroke association28 | 2010 | 8 | 15 | U | Comprehensive management | Taiwan, China | Taiwan Stroke Association |
| 8 | β-Blocker in the management of cardiovascular diseases: an expert announcement29 | 2009 | 23 | 18 | 70 | Drug intervention | Chinese mainland | Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology |
| 9 | Expert consensus on the β-blocker for the treatment of hypertension30 | 2008 | 4 | 23 | 70 | Drug intervention | Chinese mainland | The Chinese Medical Doctor Association, Evidence-Based Medicine Professional Committee |
| 10 | Uyghur diagnosis and treatment guidelines for hypertension31 | 2008 | 1 | 5 | 0 | Ethno medicine | Chinese mainland | Uyghur Medical Hospital |
| 11 | Traditional Chinese medicine for hypertension (first draft)32 | 2008 | 3 | 1 | 33 | Traditional Chinese medicine | Chinese mainland | Cardiology Branch of China Association of Chinese Traditional Medicine |
| 12 | Expert consensus on hypertension in the elderly in China33 | 2008 | 9 | 77 | 52 | Elderly people | Chinese mainland | Chinese Elderly Hypertension Treatment Consensus Committee |
| 13 | Expert consensus on long-term two hydrogen pyridine calcium channel blockers for chronic renal hypertension34 | 2008 | 1 | U | 0 | Drug intervention | Chinese mainland | Kidney Diseases Branch of the Chinese Medical Association |
| 14 | Expert consensus on the clinical application of the new fixed-dose combinations of ARB/HCTZ35 | 2007 | 3 | 18 | 0 | Drug intervention | Chinese mainland | “The new fixed-dose combinations of ARB/HCTZ” Expert Group |
| 15 | Angiotensin converting enzyme inhibitor in the management of cardiovascular diseases: a Chinese expert announcement36 | 2007 | 10 | 42 | 65 | Drug intervention | Chinese mainland | Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology |
| 16 | Hypertension—a guide to clinical practice37 | 2004 | 20 | 13 | 20 | Comprehensive management | Hong Kong, China | Hong Kong Medical Association |
| 17 | Hypertension family medication guideline38 | 2001 | 2 | 1 | 0 | Home medication | Chinese mainland | U |
ARB, angiotensin II receptor blockers; HCTZ, hydrochlorothiazide; U, unclear.